BPC-157 and TB-500 are the two peptides most often studied together in preclinical tissue research, and the two most often written about inaccurately. This article covers what each is, how they differ, why they are paired, and — importantly — how far the evidence actually extends.
BPC-157 is a pentadecapeptide — fifteen amino acids — corresponding to a partial sequence of a protein described as body protection compound, identified in gastric juice.
One of its practically useful properties is stability in aqueous solution, which is unusual for a peptide of its size and is part of why it appears frequently in in-vitro method development work.
Preclinical research has examined it in connection with angiogenic signalling and cell migration, largely in rodent models and cultured tissue.
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β4, a protein present in most mammalian cell types and one of the more abundant proteins in many of them.
Thymosin β4's established biological role involves sequestering actin monomers, which makes it relevant to how cells change shape and move. TB-500 research focuses on that region specifically, in actin polymerisation and cell-motility assays.
It is worth distinguishing TB-500 from full-length thymosin β4. They are not the same molecule, and literature about one does not automatically describe the other.
The stated rationale in the preclinical literature is that the two act on different aspects of cell migration and tissue models, so combining them tests whether the effects are additive.
That is the rationale. Whether the combination produces anything beyond the components individually has not been established, and combination studies in this area are generally small and preclinical.
Supplying them pre-combined — as in the Wolverine blend — is a practical convenience for laboratories running that comparison, removing a reconstitution and transfer step. It is not itself evidence of a combined effect.
This deserves stating directly, because the gap between the literature and the claims made about these two peptides is unusually wide.
Neither BPC-157 nor TB-500 has completed a clinical trial establishing efficacy in humans for any indication. The research base is cell culture and animal models. Findings in those models frequently do not translate to humans — that is the normal pattern in drug development, not an exception.
Neither holds a marketing authorisation as a medicine in the United Kingdom or elsewhere.
Both BPC-157 and TB-500 appear on the World Anti-Doping Agency prohibited list. For anyone conducting research in a sport-related context, or working with athlete populations, this is a material consideration independent of the scientific questions.
The current list is published by WADA and updated annually; it is the authoritative source rather than any secondary summary.
General laboratory practice for peptides of this type is to keep material sealed, frozen and protected from light, and to avoid repeated freeze-thaw cycles by aliquoting a stock solution.
Specific storage conditions for any batch are stated on its own documentation. We do not publish handling guidance that implies administration.
This article is reference material describing published research. It is not medical advice, not a therapeutic claim, and contains no dosing or administration guidance.